Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Genitourinary 1

Conditions

Pancreatic Neoplasms 70Colorectal Neoplasms 18Carcinoma, Hepatocellular 17Rectal Neoplasms 13Colonic Neoplasms 13Neoplasm Metastasis 12Esophageal Neoplasms 11Neoplasms 9Gallbladder Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Bile Duct Neoplasms 7Liver Neoplasms 6Adenocarcinoma Of Esophagus 5Breast Neoplasms 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Salivary Gland Neoplasms 3Prostatic Neoplasms 3Gastrointestinal Neoplasms 3Esthesioneuroblastoma, Olfactory 3Esophageal Squamous Cell Carcinoma 3Cholangiocarcinoma 3Urinary Bladder Neoplasms 2Pancreatic Intraductal Neoplasms 2Lung Neoplasms 2Gastrointestinal Stromal Tumors 2Carcinoma, Renal Cell 2Biliary Tract Neoplasms 2Anus Neoplasms 2Adenomatous Polyposis Coli 2

Interventions

Gemcitabine 95Cisplatin 72Capecitabine 39Oxaliplatin 38durvalumab 29Fluorouracil 27pembrolizumab 26Leucovorin 23S 1 (combination) 19Nivolumab 14Irinotecan 14lenvatinib 13Bevacizumab 13tremelimumab 10130-nm albumin-bound paclitaxel 9apatinib 8Trastuzumab 7Injections 7Immune Checkpoint Inhibitors 7Docetaxel 7Albumin-Bound Paclitaxel 7Paclitaxel 6Drug Therapy 6titanium silicide 5surufatinib 5irinotecan sucrosofate 5gemcitabine-oxaliplatin regimen 5envafolimab 5camrelizumab 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Erlotinib Hydrochloride × Gastrointestinal × Clear all
NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT03110484 2022-06-15

Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

Samsung Medical Center

Phase 2 Unknown
44 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡